Ranbaxy Laboratories Ltd. (RANB)

NSE

Currency in INR

859.80

0.00(0.00%)

Closed·01/01

Day's Range

809.45

869.70

52 wk Range

0.00

869.70

RANB Income Statement

Featured here, the Income Statement (earnings report) for Ranbaxy Laboratories Ltd., showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Period Ending:

2005

31/12

2006

31/12

2007

31/12

2008

31/12

2009

31/12

2010

31/12

2011

31/12

2012

31/12

2013

31/12

2014

31/03

Total Revenues

aa.aa

89,607.71

102,295.25

124,541.85

108,016.64

107,620.37

Total Revenues Growth

aa.aa

+17.95%

+14.16%

+21.75%

-13.27%

-0.37%

Cost Of Revenues

aa.aa

35,525.46

39,557.8

48,174.53

39,033.22

49,508.08

Gross Profit

aa.aa

54,082.25

62,737.45

76,367.32

68,983.42

58,112.29

Gross Profit Growth

aa.aa

+28.86%

+16%

+21.73%

-9.67%

-15.76%

Gross Profit Margin %

aa.aa

60.35%

61.33%

61.32%

63.86%

54%

Other Operating Expenses, Total

aa.aa

36,526.63

40,226.55

58,756.03

63,236.67

50,705.34

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+1.89%	+10.13%	+46.06%	+7.63%	-19.82%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	1,669.81	694.02	683.87	-	888.16
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	30,741.04	34,346.18	40,835.31	20,803.07	51,489.76
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	1,290.04	2,115.89	14,034.38	39,110.22	-5,149.79

Operating Income

aa.aa

17,555.62

22,510.9

17,611.29

5,746.75

7,406.95

Operating Income Growth

aa.aa

+186.75%

+28.23%

-21.77%

-67.37%

+28.89%

EBIT Margin %

aa.aa

19.59%

22.01%

14.14%

5.32%

6.88%

Net Interest Expenses

aa.aa

1,063.48

470.4

1,183.06

-2,046.07

-299.88

Net Interest Expenses Growth

aa.aa

+162.23%

-55.77%

+151.5%

-272.95%

+85.34%

Interest Expense, Total

aa.aa

-613.89

-656.78

-1,366.74

-2,046.07

-1,719.88

Interest And Investment Income

aa.aa

1,677.37

1,127.18

2,549.8

1,420

Other Non Operating Expenses, Total

aa.aa

433.94

-11,727.31

-4,244.03

-1,874.43

-6,362

EBT, Excl. Unusual Items

aa.aa

19,053.04

11,253.99

14,550.32

1,826.25

745.07

Gain (Loss) On Sale Of Assets

aa.aa

2,529.07

531.13

35.96

54.32

Other Unusual Items, Total

aa.aa

3,386.95

-38,702.61

-2,317.17

-8,498.14

-8,073.09

EBT, Incl. Unusual Items

aa.aa

20,941.86

-26,930.72

12,263.12

-7,863.55

-9,210.67

EBT, Incl. Unusual Items Growth

aa.aa

+108.06%

-228.6%

+145.54%

-164.12%

-17.13%

EBT, Incl. Unusual Items Margin

aa.aa

23.37%

-26.33%

9.85%

-7.28%

-8.56%

Income Tax Expense

aa.aa

5,848.76

1,969.34

2,939.04

2,215.84

2,961.1

Net Income to Company

aa.aa

15,093.1

-28,900.06

9,324.08

-10,079.39

-12,171.77

Minority Interest

aa.aa

-125.59

-97.23

-96.44

-36.59

61.66

Net Income

aa.aa

14,967.51

-28,997.29

9,227.64

-10,115.98

-12,110.11

Net Income Growth

aa.aa

+404.82%

-293.73%

+131.82%

-209.63%

-19.71%

Net Income Margin %

aa.aa

16.7%

-28.35%

7.41%

-9.37%

-11.25%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

14,967.51

-28,997.29

9,227.64

-10,115.98

-12,110.11

Basic EPS - Continuing Operations

aa.aa

35.57

-68.81

21.87

-23.93

-28.62

Basic EPS - Continuing Operations Growth

aa.aa

+404.4%

-293.41%

+131.78%

-209.43%

-19.61%

Diluted EPS - Continuing Operations

aa.aa

31.48

-68.81

21.78

-23.93

-28.62

Diluted EPS - Continuing Operations Growth

aa.aa

+584.91%

-318.57%

+131.65%

-209.87%

-19.61%

Basic Weighted Average Shares Outstanding

aa.aa

420.73

421.43

421.96

422.73

423.1

Diluted Weighted Average Shares Outstanding

aa.aa

449.92

421.43

423.6

422.73

423.1

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

20,381.36

25,413.94

20,611.27

8,746.73

10,604.89

EBITDA Growth

aa.aa

+131.65%

+24.69%

-18.9%

-57.56%

+21.24%

EBITDA Margin %

aa.aa

22.75%

24.84%

16.55%

8.1%

9.85%

EBIT

aa.aa

17,555.62

22,510.9

17,611.29

5,746.75

7,406.95

* In Millions of INR (except for per share items)

NSE 30

5,364.19

+25.01

+0.47%

NSE All Share

146,542.55

+728.68

+0.50%

US 30

44,456.50

+263.1

+0.60%

US 500

6,386.90

+41.8

+0.66%

FTSE 100

9,095.60

-68.71

-0.75%

DAX

24,325.66

+421.13

+1.76%

South Africa Top 40

93,358.20

+633.11

+0.68%

Market Movers

Name	Last	Chg. %	Vol.
Linkassure	1.80	+3.45%	249.20M
Prestige	1.66	+9.93%	239.85M
Fidelitybk	21.050	-1.64%	48.53M
Access Holdings	27.50	0.00%	16.41M
UAC Of Nigeria	83.85	-6.83%	5.96M
BUA Cement	174.50	-4.64%	2.10M
Okomu Oil Palm	1,050.00	0.00%	1.03M

Name	Last	Chg. %	Vol.
SCOA Nigeria	6.050	+10.00%	152.00K
Airtel Africa	2,541.50	+10.00%	101.00
Cornerst	5.83	+10.00%	23.94M
Aiico	3.19	+10.00%	20.41M
University Pre	5.610	+10.00%	324.74K
Chellarams	11.00	+4.76%	30.68K
Mansard Ins	13.310	+10.00%	3.34M

Name	Last	Chg. %	Vol.
Geregu Power	1,027.40	-10.00%	1.46K
UAC Of Nigeria	83.85	-6.83%	5.96M
Chams	2.90	-9.94%	12.45M
Northern Nigeria Flour Mills	84.00	-9.82%	38.89K
Fidson	40.500	-7.74%	434.71K
Thomaswy	3.21	-8.29%	61.03K
Transcorp Power	270.00	-6.25%	221.53K

Trending Stocks

Name	Last	Chg. %	Vol.
Aiico	3.19	+10.00%	20.41M
BUA Cement	174.50	-4.64%	2.10M
VFD PLC	13.40	+2.29%	3.56M
MTN Nigeria	464.90	-3.15%	129.34K
Jaiz Bank	4.98	+5.29%	9.30M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaa Aa A A Aaa	539.60	+34.83%	727.54
Aaa A Aaaaaaaaaa	71.90	+22.91%	88.37

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Ranbaxy Laboratories Ltd. (RANB)

RANB Income Statement

Trending Stocks